Sionna Therapeutics, Inc.
SION - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$221.24M
Close$
$1.25
67.8% downside
Current Fair Value
67.8% downsideOvervalued by 67.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $221.24 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-1.88 |
| Beta | 1.32 |
| Outstanding Shares | 45,148,971 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -2.25 |
|---|---|
| PEG | -3.44 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.65
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.64
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 558.01% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 106.79% |
|---|---|
| Total Invested | $1,189▼ 100.00% |
| Investors Holding | 1▼ 156.00% |
About Sionna Therapeutics, Inc.
59 employees
CEO: Michael Cloonan
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibro...